CANCER INVESTIGATION癌症研究
CANCER INVESTIGATION(英文缩写 CANCER INVEST),ISSN 0735-7907,eISSN 1532-4192,中文译名:癌症研究 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.368 | Q4 |
| 2022 | 2.400 | Q4 |
| 2023 | 1.800 | Q3 |
| 2024 | 1.900 | Q3 |
| 2025 | 2.200 | Q3 |
CANCER INVESTIGATION 最新收录文献
-
1. Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.
PMID:日期:2026-10-01The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). Using Surveillance, Epidemiology and End Results (SEER) data, we analyzed 20,970 patients with PCLs and evaluated standardized incidence ratios (SIRs) and survival outcomes of SPTs stratified by lymphoma subtype (indolent vs. aggressive). A total of 2,589 SPTs were identified (SIR = 1.40, 95% CI 1.35-1.45), with significantly elevated risks across sex, ethnicity, stage, latency, year of diagnosis, and treatment. Both indolent and aggressive CTCLs were associated with increased SPT risk, with SIRs of 1.27 (1.16-1.39) and 1.38 (1.11-1.69), respectively. Lymphatic and hematopoietic malignancies predominated in indolent CTCLs, along with thyroid cancer, whereas aggressive CTCLs were mainly associated with extranodal non-Hodgkin lymphoma and myeloma. Increased SPT incidence was also observed in indolent and aggressive CBCLs (SIR = 1.49 and 1.38), with indolent CBCLs showing a broad SPT spectrum including lung cancer and cutaneous melanoma. Patients younger than 30 years, with stage I disease or aggressive PCLs, had decreased age-adjusted overall and disease-specific survival, indicating a need for more intensive surveillance.
-
2. Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.
PMID:日期:2026-10-01The treatment landscape for multiple myeloma (MM) has evolved significantly over the years; however, the disease remains incurable. Heavily pretreated patients with refractory disease to anti-CD38 therapies, proteasome inhibitors (PIs), and immunomodulatory drugs (IMiDs) face a very poor prognosis. Bispecific antibodies (BsAbs) are the newest, and most promising available therapy for heavily pretreated patients with relapsed refractory multiple myeloma (RRMM). BsAbs primarily rely on T cell activation to target cancer cells by binding malignant plasma cells to cytotoxic T cells via surface antigens. BsAbs consist of two binding sites: one that targets a specific antigen on the surface of MM cells, such as B-cell maturation antigen (BCMA), G-protein-coupled receptor class C group 5 member D (GPRC5D), or fragment crystallizable receptor-like 5 (FcRH5), and another that binds to CD3, a T-cell receptor. Ongoing research aimed at optimizing sequencing strategies, mitigating toxicity, and evaluating combination approaches will be critical to maximizing the durability of response and improving long-term outcomes in this high-risk population.
-
3. The Association of NSCLC and Dementia - A Population-Based Cohort Study in Taiwan.
PMID:日期:2026-10-01The relationship between cancer and dementia remains complex, and evidence regarding non-central nervous system (CNS) cancers such as non-small cell lung cancer (NSCLC) is inconsistent. This population-based cohort study examined the association between stage II-III NSCLC and the risk of dementia in Taiwan. National Health Insurance Research Database (NHIRD) was used in this study. The primary outcome was incident dementia, defined by ≥2 outpatient visits or ≥1 hospitalization. Cox proportional hazards models were applied to estimate crude and adjusted hazard ratios (HR). Kaplan-Meier curves and Schoenfeld residual tests were used to assess cumulative incidence and proportional hazards assumptions. The median follow-up time was 3.1 years in the NSCLC cohort and 4.7 years in the non-cancer cohort. Overall, stage II-III NSCLC was not associated with an increased risk of dementia compared with matched non-cancer individuals (adjusted HR = 1.11, 95% Confidence Interval (CI): 0.98-1.26). However, Patients with stage II NSCLC showed a borderline significance toward increased dementia risk (adjusted HR = 1.20, 95% CI: 1.01-1.43), although this association was not maintained in sensitivity analyses. Age, hypertension, diabetes mellitus, and cerebrovascular diseases were also associated with elevated dementia risk. This large, nationwide cohort study found no overall association between stage II-III NSCLC and dementia.
-
4. Spatial Transcriptomics Open a New Era of Pan-Cancer Analysis.
PMID:日期:2026-10-01Spatial transcriptomics (ST) is revolutionizing pan-cancer analysis by enabling the in situ integration of spatial architecture with molecular profiles. This review synthesizes key advances, including deciphering conserved and divergent spatial ecosystems across cancers, mapping the heterogeneity of driver genes, tracing metastatic evolution, and establishing novel spatial molecular classifications. It further discusses how these insights inform clinical translation for diagnosis and therapy stratification. While integration of multi-cancer datasets and translational efficiency remain challenges, ST is a pivotal bridge toward spatially informed, broad-spectrum oncological strategies.
-
5. Quantifying the Mediation Effect of Disease Stage on Racial Disparities in Head and Neck Cancer Survival.
PMID:日期:2026-10-01There are significant racial and ethnic disparities in head and neck cancer (HNC) survival. Disparities in cancer stage appear to account for some of the disparities in survival. However, the proportion of the survival disparities mediated by cancer stage is unclear. This study aimed to quantify the mediation effects of stage at diagnosis on racial/ethnic disparities in HNC survival using data from the California Cancer Registry. We found that T3-4 disease accounted for 36.3% (95% CI 15.6% to 57.0%) of the association between Black (versus White) and worse OS, and for 44.2% (95% CI 10.9% to 77.4%) of the association between Black (versus White) and worse DSS. This suggests that interventions aimed at improving access to care and early detection of malignancies may have highest impact in reducing racial/ethnic disparities in HNC survival. Future studies are needed to further understand factors that drive racial disparities in HNC stage at diagnosis, and to inform the development of intervention strategies to address these disparities.
-
6. Efficacy and Safety of Pembrolizumab in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.
PMID:日期:2026-10-01This meta-analysis integrates data from 7 randomized controlled trials comprising 4,560 patients with advanced gastric cancer to evaluate the efficacy and safety of pembrolizumab as monotherapy or in combination with chemotherapy. Compared to control treatments, pembrolizumab significantly improved overall survival and objective response rate, though no significant difference was observed in progression-free survival. While the risk of immune-related adverse events and severe treatment-related adverse events increased with pembrolizumab, the incidence of all-grade adverse events was not significantly different. Importantly, pembrolizumab was not associated with an increased risk of treatment-related death (OR = 0.99, 95% CI 0.59-1.65), indicating that the risk of fatal adverse events is comparable to that of chemotherapy alone. This finding helps address a common clinical concern regarding the safety profile of immunotherapy. Subgroup analyses revealed that patients with PD-L1 combined positive score of 10 or higher derived the greatest benefit in objective response rate and progression-free survival. Combination therapy demonstrated superior efficacy over monotherapy across all survival outcomes but was associated with higher immune-related toxicity. Based on these findings, pembrolizumab in combination with chemotherapy is recommended as first-line treatment for patients with good performance status and PD-L1 combined positive score of 10 or higher. For elderly patients or those with reduced performance status, monotherapy may offer a favorable balance between efficacy and safety. Routine PD-L1 testing and proactive adverse event management are essential for optimizing treatment outcomes.
-
7. Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?
PMID:日期:2026-10-01该文献暂无摘要。
-
8. Prognostic Value of miR-145 in HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma Treated with Disitamab Vedotin.
PMID:日期:2026-10-01Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate, has shown promising activity in locally advanced or metastatic urothelial carcinoma (la/mUC), but clinically useful biomarkers remain lacking. In this retrospective single-center real-world study, we evaluated the efficacy of RC48 and the clinical relevance of tumor miR-145 expression in 136 patients with HER2-positive la/mUC treated between June 2022 and October 2024. Clinical outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). The ORR and DCR were 64.0% and 75.7%, respectively. Median OS was 15.5 months (95% CI: 12.6-28.5), and median PFS was 9.2 months (95% CI: 7.1-11.8). In univariate Cox analysis, miR-145 was the only variable significantly associated with OS (HR = 0.676, = 0.002). High miR-145 expression was associated with improved OS and a higher complete response rate than low expression. Time-dependent ROC analysis showed an AUC of 76.3% at 2 years, and decision curve analysis suggested potential clinical utility. These findings indicate that miR-145 may serve as a candidate prognostic biomarker for risk stratification in RC48-treated la/mUC.
-
9. Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.
9. 卡博替尼治疗肾细胞癌的性别特异性不良事件和心血管毒性：一项为期九年的药物警戒研究PMID:日期:2026-10-01Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in advanced renal cell carcinoma (RCC). However, real-world evidence regarding its safety profile, particularly sex-specific adverse events (AEs) and cardiovascular toxicity, remains limited. A retrospective pharmacovigilance study was performed using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from Q2 2016 to Q2 2025. Reports listing cabozantinib as the primary suspected drug and RCC as the indication were included. Disproportionality analyses using Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) were conducted to identify safety signals. Sex-specific differences were evaluated using a modified 2 × 2 contingency table. Time-to-onset (TTO) was assessed with Weibull distribution modeling. Cardiovascular toxicity was further analyzed using standardized MedDRA queries (SMQs) and compared with sunitinib. A total of 22,778 cabozantinib-related AE reports were identified, with a male-to-female ratio of 2.41:1 and a median age of 65 years. Major safety signals involved gastrointestinal, endocrine, and metabolic disorders, with strong associations observed for palmar-plantar erythrodysesthesia syndrome, stomatitis, oral pain, and taste disturbance. The median TTO was 40 days, with a Weibull shape parameter < 1, indicating an early-onset pattern. Females showed higher reporting of gastrointestinal and dermatologic AEs, while males had higher frequencies of severe outcomes, including acute myocardial infarction. Cabozantinib demonstrated a lower overall cardiovascular AE signal (ROR = 0.70, 95% CI: 0.66-0.75) compared with sunitinib (ROR = 0.87, 95% CI: 0.82-0.91). This real-world study highlights sex-specific safety differences, early AE onset, and a comparatively favorable cardiovascular profile of cabozantinib, supporting individualized monitoring strategies in RCC treatment.
-
10. Construction and Validation of a Nomogram Model for Predicting Cancer-Specific Survival in Colorectal Cancer Based on the SEER Database.
PMID:日期:2026-09-19Colorectal cancer (CRC) remains one of the most prevalent malignancies worldwide, and accurate prognostic prediction is essential for individualized prognostic assessment and patient risk communication. The conventional TNM staging system has limited capacity for personalized survival estimation. This study aimed to construct and validate a registry-based nomogram model for predicting 3-year and 5-year cancer-specific survival (CSS) in CRC patients using data from the Surveillance, Epidemiology, and End Results (SEER) database. A retrospective cohort study was conducted using data from the SEER database (2010-2015), an interval selected to ensure consistent AJCC 7th edition staging and adequate follow-up for 5-year CSS assessment. A total of 45,218 CRC patients who met the inclusion criteria were randomly divided into a training cohort (n = 31,653) and a validation cohort (n = 13,565) at a 7:3 ratio. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent prognostic factors for CSS. A nomogram was constructed based on these factors. Model performance was assessed by concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA), with DCA interpreted as an evaluation of prognostic risk-classification net benefit rather than as evidence for treatment selection. Eight independent prognostic factors were identified: age at diagnosis, race, marital status, tumor grade, T stage, N stage, M stage, and carcinoembryonic antigen (CEA) level. The C-index of the nomogram was 0.783 (95% CI: 0.776-0.790) in the training cohort and 0.771 (95% CI: 0.761-0.781) in the validation cohort, both higher than the AJCC TNM staging system (training: 0.724; validation: 0.716). The absolute C-index improvements over TNM staging were 0.059 and 0.055 in the training and validation cohorts, respectively. The area under the ROC curve (AUC) for 3-year and 5-year CSS prediction was 0.812 and 0.794 in the training cohort, respectively, and 0.798 and 0.781 in the validation cohort. Calibration curves demonstrated close agreement between predicted and observed survival probabilities. DCA indicated that the nomogram provided higher net benefit for prognostic risk classification than the traditional TNM staging system across a wide range of threshold probabilities. The nomogram model incorporating clinicopathological and demographic variables showed higher predictive accuracy than conventional TNM staging for CSS in CRC patients. Because the incremental gains over TNM staging were moderate and the model was developed from registry data without detailed chemotherapy information or molecular biomarkers, including MSI status, this tool should be interpreted only as an adjunct for individualized prognostic assessment and risk communication. It should not be used to determine treatment intensity or to replace guideline-based therapeutic decision-making, and it requires external validation in contemporary cohorts.